Published in Hospital Business Week, August 12th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Boston Scientific Corporation.
Report 1: Boston Scientific Corporation (NYSE:BSX) announced that it has completed enrollment in the European and Intercontinental phases (II and III) of its TAXUS OLYMPIA registry, bringing the total number of current patients to more than 23,000. The registry is designed to evaluate the safety and performance of the Company's second-generation drug-eluting coronary stent (DES), TAXUS(R) Liberte(TM)(1), in a real-world...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.